Beta-Caryophyllene / JNK Cancer Research Results

BCP, Beta-Caryophyllene: Click to Expand ⟱
Features:

β-Caryophyllene is a dietary sesquiterpene and CB2 agonist with preclinical anticancer evidence, including apoptosis induction, reduced proliferation, anti-angiogenesis, reduced invasion/migration, and chemo/radio-sensitization. Evidence is promising but remains mainly in-vitro and animal-based; clinical cancer validation is lacking.
-naturally occurring sesquiterpene found in many plant essential oils: black pepper, clove oil ...

Beta-Caryophyllene — β-Caryophyllene is a plant-derived bicyclic sesquiterpene hydrocarbon and dietary cannabinoid with selective functional agonism at cannabinoid receptor type 2. It is formally classified as a natural sesquiterpene terpene, food flavoring compound, and investigational phytochemical adjunct rather than an approved anticancer drug. Standard abbreviations include BCP, β-CP, and sometimes trans-caryophyllene. It occurs in multiple essential oils, especially black pepper, clove, copaiba, oregano, hops, rosemary, and Cannabis sativa chemotypes, but its database identity should be the purified compound rather than a whole-oil product.

Primary mechanisms (ranked):

  1. CB2-centered anti-inflammatory and immunomodulatory signaling, with low CB1 activity and therefore no intrinsic THC-like psychoactive classification.
  2. Suppression of pro-survival oncogenic signaling, especially PI3K/Akt/mTOR, STAT3, NF-κB, and related proliferation or survival pathways in cancer models.
  3. Induction of mitochondrial apoptosis through Bax/Bcl-2 shift, caspase activation, mitochondrial stress, and cell-cycle arrest in several cancer cell lines.
  4. Anti-angiogenic and anti-migratory activity, including inhibition of endothelial migration, tube formation, VEGF-linked responses, EMT, invasion, and metastasis-associated phenotypes.
  5. Chemosensitization, mainly preclinical, reported with cisplatin and other cytotoxic or targeted agents; mechanism appears context-dependent and partly linked to apoptosis and resistance-pathway modulation.
  6. Radiosensitization, currently preliminary and model-dependent, with recent colorectal cancer cell evidence involving PPARγ-mediated apoptosis.
  7. ROS/NRF2 modulation is secondary and context-dependent: BCP can promote oxidative stress in cancer-cell apoptosis models, while in normal injury models it more often shows cytoprotective antioxidant and NRF2-linked effects.

Bioavailability / PK relevance: BCP is highly lipophilic and formulation-sensitive; oral exposure is limited and variable with conventional dosing, while self-emulsifying lipid formulations can substantially improve human systemic exposure. PK relevance is high because many in-vitro anticancer concentrations are unlikely to be reproduced by normal dietary intake.

Delivery constraints: The key delivery constraints are volatility, hydrophobicity, oxidation/stability, low aqueous solubility, food-matrix dependence, and the likely need for lipid, nanoemulsion, SEDDS, or other formulation strategies if systemic pharmacology is the goal.

In-vitro vs systemic exposure relevance: Most anticancer assays use micromolar-to-high-micromolar or µg/mL concentrations; these should be interpreted cautiously because common in-vitro levels likely exceed exposures achievable from culinary intake. Formulated oral BCP may improve exposure, but clinical anticancer target engagement has not been established.

Clinical evidence status: Preclinical oncology evidence is moderate and spans cell, endothelial, and animal models; human evidence is small and mostly non-oncology or PK-focused. No validated clinical cancer efficacy evidence was found. Best database status is preclinical / investigational adjunct, with possible chemosensitizer and anti-angiogenic tags marked as preclinical.

Beta-Caryophyllene Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 CB2 receptor signaling CB2 engagement may shift inflammatory and survival signaling ↓ (context-dependent) CB2-mediated inflammation ↓ with low CB1 psychoactivity R/G Anti-inflammatory and immunomodulatory signaling Core pharmacologic identity of BCP; direct anticancer dependence on CB2 varies by model.
2 PI3K Akt mTOR STAT3 survival signaling PI3K/Akt/mTOR ↓; STAT3 ↓; proliferation ↓; survival ↓ Usually cytoprotective or neutral at lower exposure (context-dependent) R/G Growth suppression and apoptosis sensitization Central anticancer axis across bladder, ovarian, lung, and other cell models; not yet clinically validated.
3 Mitochondrial apoptosis Bax ↑; Bcl-2 ↓; caspase-3 ↑; mitochondrial stress ↑; apoptosis ↑ In injury models, mitochondrial dysfunction often ↓ G Intrinsic apoptotic cell death Strong recurring preclinical mechanism; cancer selectivity depends on dose and model.
4 Angiogenesis and endothelial migration VEGF-linked angiogenesis ↓; invasion ↓; migration ↓ Endothelial migration and tube formation ↓ (model-dependent) G Anti-angiogenic and anti-metastatic pressure Important for colorectal xenograft and endothelial assay interpretation; may be therapeutically relevant but exposure-limited.
5 NF-κB inflammatory signaling NF-κB-linked survival and cytokine tone ↓ (context-dependent) Inflammatory cytokine signaling ↓ R/G Inflammation-linked tumor support reduction More robust as an anti-inflammatory mechanism than as a standalone cancer-killing mechanism.
6 ROS and mitochondrial oxidative stress ROS ↑ can contribute to apoptosis (high concentration only) Oxidative stress ↓ in many toxic injury models R/G Context-dependent redox modulation antioxidant or pro-oxidant; direction depends on cell type, injury context, and concentration.
7 NRF2 cytoprotection ↔ or context-dependent; may be undesirable if it protects malignant cells NRF2/HO-1/NQO1 ↑ in injury-protection models G Secondary antioxidant-response modulation NRF2 is not a core anticancer mechanism for BCP; tag as secondary/contextual rather than primary.
8 Chemosensitization Cisplatin response ↑; apoptosis ↑; resistance signaling ↓ (model-dependent) Normal-cell toxicity data are insufficient for oncology combinations G Adjunct sensitization Preclinical evidence supports a sensitizer hypothesis, but there is no clinical cancer validation.
9 Radiosensitization Radiation response ↑ in colorectal cancer cells (model-dependent) Normal-tissue radioprotection versus radiosensitization is unresolved G Potential radiation adjunct Recent evidence is early and should be tagged as preliminary, not established.
10 Glycolysis and HIF-1α ↔ limited direct oncology evidence ↔ not a primary established axis G Not a core mechanism Do not add strong HIF-1α or glycolysis tags unless future product-specific cancer evidence supports them.
11 Clinical Translation Constraint Effective in-vitro exposure may exceed practical dietary exposure Food-use safety does not establish therapeutic-dose safety G PK and evidence limitation Key constraints are bioavailability, formulation, dose, tissue exposure, cancer-type heterogeneity, and lack of oncology trials.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
JNK, c-Jun N-terminal kinase (JNK): Click to Expand ⟱
Source:
Type:
JNK acts synergistically with NF-κB, JAK/STAT, and other signaling molecules to exert a survival function. Janus signaling promotes cancer cell survival.
JNK, or c-Jun N-terminal kinase, is a member of the mitogen-activated protein kinase (MAPK) family. It plays a crucial role in various cellular processes, including cell proliferation, differentiation, and apoptosis (programmed cell death). JNK is activated in response to various stress signals, such as UV radiation, oxidative stress, and inflammatory cytokines.
JNK activation can promote apoptosis in cancer cells, acting as a tumor suppressor. However, in other contexts, it can promote cell survival and proliferation, contributing to tumor progression.

JNK is often unregulated in cancers, leading to increased cancer cell proliferation, survival, and resistance to apoptosis. This activation is typically associated with poor prognosis and aggressive tumor behavior.
Scientific Papers found: Click to Expand⟱
6495- BCP,    Beta-caryophyllene is a dietary cannabinoid
*CB2 / CNR2↑, *other↝, *Inflam↓, *TNF-α↓, *IL1β↓, *ERK↓, *JNK↓,
6391- Eug,  BCP,  5-FU,    Exploring Mechanism of Actions for Eugenol and Beta-Caryophyllene to Combat Colorectal Cancer Chemotherapy Using Network Pharmacology
- in-vitro, CRC, HCT116
eff↑, ChemoSen↑, HSP90↓, Dose↝, TumAuto↑, Apoptosis↑, PI3K↓, Akt↓, mTOR↓, JNK↓, p38↓, EMT↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   JNK↓, 1,   p38↓, 1,  

Protein Folding & ER Stress ⓘ

HSP90↓, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   mTOR↓, 1,   PI3K↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose↝, 1,   eff↑, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

CB2 / CNR2↑, 1,  

Cell Death ⓘ

JNK↓, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  
Total Targets: 7

Scientific Paper Hit Count for: JNK, c-Jun N-terminal kinase (JNK)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:401  Target#:168  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page